Cargando…

Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression‐free survival based on reconstructed individual patient data

BACKGROUND: In patients with advanced melanoma, immune‐checkpoint inhibitors (ICIs) represent the mainstay for first line treatment. Recently, relatlimab+nivolumab was proposed as a new combination therapy. This review was aimed at summarizing the current data of effectiveness for ICIs. Progression‐...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ossato, Andrea, Damuzzo, Vera, Baldo, Paolo, Mengato, Daniele, Chiumente, Marco, Messori, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	REVIEWS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939083/ https://www.ncbi.nlm.nih.gov/pubmed/35920297 http://dx.doi.org/10.1002/cam4.5067

Ejemplares similares

Progression-Free and Overall Survival of First-Line Treatments for Advanced Renal Cell Carcinoma: Indirect Comparison of Six Combination Regimens
por: Ossato, Andrea, et al.
Publicado: (2023)

The “One-to-Many” Survival Analysis to Evaluate a New Treatment in Comparison With Therapeutic Alternatives Based on Reconstructed Patient Data: Enfortumab Vedotin Versus Standard of Care in Advanced or Metastatic Urothelial Carcinoma
por: Messori, Andrea, et al.
Publicado: (2022)

Application of the IPDfromKM-Shiny Method to Compare the Efficacy of Novel Treatments Aimed at the Same Disease Condition: A Report of 14 Analyses
por: Messori, Andrea, et al.
Publicado: (2023)

Analysis of Survival Curves: Statistical Methods Accounting for the Presence of Long-Term Survivors
por: Damuzzo, Vera, et al.
Publicado: (2019)

Axicabtagene ciloleucel in non-Hodgkin lymphoma: the restricted mean survival time as a tool for estimating progression-free life expectancy better than the median
por: Messori, Andrea, et al.
Publicado: (2020)

The Degree of Programmed Death-Ligand 1 (PD-L1) Positivity as a Determinant of Outcomes in Metastatic Triple-Negative Breast Cancer Treated With First-Line Immune Checkpoint Inhibitors
por: Di Spazio, Lorenzo, et al.
Publicado: (2022)

COVID-19 impact on skills and professional perceptions of the hospital pharmacist during the first outbreak wave
por: Damuzzo, Vera, et al.
Publicado: (2022)

Efficacy of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient or Microsatellite Instability-High Metastatic Colorectal Cancer: Analysis of Three Phase-II Trials
por: Cancanelli, Luca, et al.
Publicado: (2021)

Treatments for Relapsed-Refractory Diffuse Large B-cell Lymphoma: A Preliminary Evaluation of the Place in Therapy of Glofitamab, a Bispecific Monoclonal Antibody
por: Messori, Andrea, et al.
Publicado: (2022)

SARS-COV-2 pandemic: establishing three risk levels for 19 Italian regions and two autonomous provinces
por: Messori, Andrea, et al.
Publicado: (2022)

Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments
por: Cancanelli, Luca, et al.
Publicado: (2023)

Medical Therapy, Radiofrequency Ablation, or Cryoballoon Ablation as First-Line Treatment for Paroxysmal Atrial Fibrillation: Interpreting Efficacy Through the Shiny Method
por: Trippoli, Sabrina, et al.
Publicado: (2022)

The QOSMOS Study: Pharmacist-Led Multicentered Observational Study on Quality of Life in Multiple Sclerosis
por: Damuzzo, Vera, et al.
Publicado: (2021)

Differences in Effectiveness among Devices for Endovascular Thrombectomy in Patients with Acute Ischemic Stroke
por: Chiumente, Marco, et al.
Publicado: (2016)

CAR‐T treatment: Determining the progression‐free survival gain in patients with heavily pretreated multiple myeloma
por: Messori, Andrea
Publicado: (2020)

Burden of uterine fibroids in Italy: epidemiology, treatment outcomes, and consumption of health care resources in more than 5,000 women
por: Chiumente, Marco, et al.
Publicado: (2017)

Synthetizing Published Evidence on Survival by Reconstruction of Patient-Level Data and Generation of a Multi-Trial Kaplan-Meier Curve
por: Messori, Andrea
Publicado: (2021)

Preparation of intravenous chemotherapy bags: evaluation of a dose banding approach in an Italian oncology hospital
por: Chiumente, Marco, et al.
Publicado: (2021)

Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in Melanoma
por: Ammann, Nadine L., et al.
Publicado: (2022)

Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors
por: Mesti, Tanja, et al.
Publicado: (2023)

Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors
por: Mantia, Charlene M., et al.
Publicado: (2021)

Lutetium in prostate cancer: Reconstruction of patient-level data from published trials and generation of a multi-trial Kaplan-Meier curve
por: Messori, Andrea
Publicado: (2022)

Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma
por: Amdahl, Jordan, et al.
Publicado: (2016)

Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti–PD-1 Era
por: Lamba, Nayan, et al.
Publicado: (2022)

Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma
por: Krebs, Franziska K., et al.
Publicado: (2021)

Optimization of resources by drug management: A multicentred web-administered study on the use of ipilimumab in Italy
por: Damuzzo, V, et al.
Publicado: (2018)

First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma
por: Wang, Xuechen, et al.
Publicado: (2021)

Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
por: Petrova, Vera, et al.
Publicado: (2020)

Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients
por: Fässler, Mirjam, et al.
Publicado: (2019)

Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
por: Klemen, Nicholas D., et al.
Publicado: (2020)

The Role of Immune Checkpoint Blockade in Uveal Melanoma
por: Wessely, Anja, et al.
Publicado: (2020)

Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma
por: Klemen, Nicholas D., et al.
Publicado: (2019)

Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition—A Pooled Analysis of Patients With Advanced Melanoma
por: Regan, Meredith M., et al.
Publicado: (2019)

Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067
por: Regan, Meredith M, et al.
Publicado: (2021)

Clinical and Molecular Characteristics Associated with Survival in Advanced Melanoma Treated with Checkpoint Inhibitors
por: Badami, Sunil, et al.
Publicado: (2018)

Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors †
por: de Glas, Nienke A., et al.
Publicado: (2021)

Early and intermediate survival after transcatheter aortic valve implantation: systematic review and meta-analysis of 14 studies
por: Messori, Andrea, et al.
Publicado: (2013)

The restricted mean survival time as a replacement for the hazard ratio and the number needed to treat in long‐term studies
por: Messori, Andrea, et al.
Publicado: (2021)

Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1 January and 28 February 2021
por: Ossato, Andrea, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Melanoma and HIV Infection
por: Marra, Antonio, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vmgvuucpm3uu7tj33qcq8b6500